Last reviewed 2026-05-14 · How we verify

Rimegepant 75mg daily dosing (rimegepant-75mg-daily-dosing)

Rimegepant 75mg daily dosing (generic name: rimegepant-75mg-daily-dosing) is a calcitonin gene-related peptide receptor antagonist drug developed by Pfizer. It is currently FDA-approved for Acute treatment of migraine attacks with or without aura in adults, Prevention of migraine attacks in adults.

Rimegepant is a calcitonin gene-related peptide receptor antagonist that inhibits the release of pro-inflammatory peptides.

Rimegepant 75mg daily dosing, developed by Pfizer, holds a significant market position as a calcitonin gene-related peptide receptor antagonist, targeting patients with moderate-to-severe migraine attacks. Its competitive advantage lies in its unique mechanism of action, which differentiates it from milder treatments like acetaminophen and NSAIDs, and provides an alternative to triptans, antidepressants, and antiepileptics. A key risk is the lack of clinical trial data to support its efficacy and safety, which may limit its adoption and regulatory approvals. The pipeline outlook remains uncertain due to the requirement for a PD-L1 companion diagnostic for several indications, potentially delaying further development and market expansion.

At a glance

Mechanism of action

Rimegepant works by binding to the calcitonin gene-related peptide receptor, which is a key player in the pathophysiology of migraine. This binding action inhibits the release of pro-inflammatory peptides, such as calcitonin gene-related peptide (CGRP), that are involved in the development of migraine symptoms. By reducing the levels of these peptides, rimegepant helps to alleviate migraine symptoms and prevent future attacks.

Approved indications

• Acute treatment of migraine attacks with or without aura in adults
• Prevention of migraine attacks in adults

Common side effects

• Nasopharyngitis
• COVID-19

Drug interactions

• Warfarin
• P-glycoprotein inhibitors (e.g., cyclosporine, ketoconazole)
• P-glycoprotein inducers (e.g., rifampin, St. John's Wort)
• CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)
• CYP3A4 inducers (e.g., rifampin, St. John's Wort)
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)
• Strong CYP3A4 inducers (e.g., rifampin, St. John's Wort)

Key clinical trials

• Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Rimegepant 75mg daily dosing CI brief — competitive landscape report
• Rimegepant 75mg daily dosing updates RSS · CI watch RSS
• Pfizer portfolio CI

Frequently asked questions about Rimegepant 75mg daily dosing

Related

• Drug class: All calcitonin gene-related peptide receptor antagonist drugs
• Target: All drugs targeting calcitonin gene-related peptide receptor
• Manufacturer: Pfizer — full pipeline
• Therapeutic area: All drugs in Neuroscience
• Indication: Drugs for Acute treatment of migraine attacks with or without aura in adults
• Indication: Drugs for Prevention of migraine attacks in adults
• Compare: Rimegepant 75mg daily dosing vs similar drugs
• Pricing: Rimegepant 75mg daily dosing cost, discount & access